¼¼°èÀÇ ÀçÅà »ê¼Ò¹ß»ý±â ½ÃÀå
Homecare Oxygen Concentrators
»óǰÄÚµå : 1744738
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 379 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,026,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,080,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÀçÅà »ê¼Ò¹ß»ý±â ¼¼°è ½ÃÀåÀº 2030³â±îÁö 18¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 13¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÀçÅà »ê¼Ò¹ß»ý±â ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 18¾ï ´Þ·¯¿¡ ´ÞÇϰí, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 5.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÈÞ´ë¿ë ÀçÅà »ê¼Ò¹ß»ý±â´Â ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß Çϳª·Î CAGRÀº 7.1%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 12¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °íÁ¤Çü ÀçÅà »ê¼Ò¹ß»ý±â ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 3.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 3¾ï 5,620¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÀçÅà »ê¼Ò¹ß»ý±â ½ÃÀåÀº 2024³â¿¡ 3¾ï 5,620¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 3¾ï 8,000¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 9.6%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 2.8%¿Í 5.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÀçÅà »ê¼Ò¹ß»ý±â ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÀçÅà »ê¼Ò¹ß»ý±â°¡ ¸¸¼º È£Èí±â Ä¡·á¿¡ ÇʼöÀûÀÎ Á¸Àç°¡ µÇ°í ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

ÀçÅà »ê¼Ò¹ß»ý±â´Â COPD, Æó¼¶À¯Áõ, COVID-19ÀÇ Àå±âÀûÀÎ ¿µÇâ°ú °°Àº ¸¸¼º È£Èí±âÁúȯÀ» °ü¸®Çϴ ȯÀڵ鿡°Ô Áß¿äÇÑ ÀÇ·á Àåºñ°¡ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ ±â±âµéÀº ÁÖº¯ °ø±â¿¡¼­ »ê¼Ò¸¦ ÃßÃâÇÏ°í ³óÃàÇÏ¿© Áý¿¡¼­ »ê¼Ò Ä¡·á¸¦ ÇÒ ¼ö ÀÖ°ÔÇÔÀ¸·Î½á ¾ÐÃà °¡½ºÅëÀ» ´ëüÇÒ ¼ö ÀÖ´Â º¸´Ù ¾ÈÀüÇÏ°í Æí¸®ÇÑ ´ë¾ÈÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è Àα¸ÀÇ °í·ÉÈ­¿Í È£Èí±âÁúȯÀÇ Áõ°¡·Î ÀÎÇØ ½Å·ÚÇÒ ¼ö ÀÖ°í ÄÄÆÑÆ®ÇÏ¸ç »ç¿ëÇϱ⠽¬¿î »ê¼Ò¹ß»ý±â¿¡ ´ëÇÑ ¼ö¿ä°¡ ºü¸£°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÆÒµ¥¹Í ÀÌÈÄ ÀçÅÃÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ È£Èí±â °ü¸®¿¡¼­ »ê¼Ò¹ß»ý±âÀÇ Á߿伺ÀÌ ´õ¿í ºÎ°¢µÇ°í ÀÖÀ¸¸ç, ƯÈ÷ Áö¼ÓÀû ¶Ç´Â Àå±âÀûÀÎ »ê¼Ò °ø±ÞÀÌ ÇÊ¿äÇÑ È¯ÀÚ¿¡°Ô´Â ´õ¿í Áß¿äÇØÁ³½À´Ï´Ù. ÀÔ¿øÀ» ÁÙÀÌ°í »îÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö Àֱ⠶§¹®¿¡ ³óÃà±â´Â ȯÀÚ¿Í ÀÇ·á ¼­ºñ½º Á¦°øÀÚ ¸ðµÎ¿¡°Ô ¸Å·ÂÀûÀÔ´Ï´Ù. °³¹ß º¸Á¶±Ý, º¸Çè ȯ±Þ ¹× °øÁß º¸°Ç ÇÁ·Î±×·¥Àº ¼±Áø±¹°ú ½ÅÈï ½ÃÀå ¸ðµÎ¿¡¼­ Á¢±Ù¼ºÀ» È®´ëÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. È޴뼺, ºñ¿ë È¿À²¼º ¹× ³·Àº À¯Áöº¸¼ö¼ºÀ¸·Î ÀÎÇØ Àå±âÀûÀÎ ÀçÅà ġ·á¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

µðÀÚÀΰú ±â¼úÀÇ ¹ßÀüÀÌ È¯ÀÚÀÇ ¿¹Èĸ¦ ¾î¶»°Ô °³¼±Çϰí Àִ°¡?

ÃÖ±Ù ±â¼ú Çõ½ÅÀº ÀçÅà »ê¼Ò¹ß»ý±âÀÇ ±â´É°ú »ç¿ë°¨À» Å©°Ô º¯È­½Ã۰í ÀÖ½À´Ï´Ù. ÃֽŠÀåºñ´Â °¡º±°í, ¼ÒÀ½ÀÌ Àû°í, ¿¡³ÊÁö È¿À²ÀÌ ³ôÀ¸¸ç, °íÁ¤½Ä ¹× ÈÞ´ë¿ë ¸ðµÎ¿¡ ÀûÇÕÇÑ ÄÄÆÑÆ®ÇÑ Å©±â·Î ¼³°èµÇ¾úÀ¸¸ç, AC Àü¿ø ¹× ¹èÅ͸® Àü¿ø µà¾ó ¸ðµå ÀåÄ¡¸¦ ÅëÇØ ȯÀÚ°¡ À̵¿ Áß¿¡µµ Áß´Ü ¾øÀÌ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ÆÞ½º Åõ¿©, À¯·® ÀÚµ¿ Á¶Àý, °íµµ º¸Á¤ ±â´ÉÀÌ Ãß°¡µÇ¾î ´Ù¾çÇÑ È°µ¿ ¼öÁذú ȯ°æ¿¡ ´ëÇÑ ÀûÀÀ¼ºÀÌ Çâ»óµÇ¾ú½À´Ï´Ù.

µðÁöÅÐ ¿¬°áµµ »õ·Î¿î Æ®·»µåÀÔ´Ï´Ù. ½º¸¶Æ® ³óÃà±â´Â ÇöÀç ºí·çÅõ½º ¹× ¾Û°úÀÇ ÅëÇÕÀ» ÅëÇØ ȯÀÚ¿Í °£º´ÀÎÀÌ »ç¿ë·®, »ê¼Ò ¼øµµ, À¯Áöº¸¼ö ¾Ë¸²À» ½Ç½Ã°£À¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â ±â´ÉÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â´ÉÀ» ÅëÇØ ÄÄÇöóÀ̾𽺸¦ °³¼±ÇÏ°í °íÀåÀ» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ºÐÀÚ Ã¼ ±â¼ú, ÄÄÇÁ·¹¼­ ¼ÒÇüÈ­, ¿­ °ü¸® ½Ã½ºÅÛÀÇ ¹ßÀüÀ¸·Î ÀÛµ¿ ¼ö¸íÀ» ¿¬ÀåÇϰí Á¤¼÷¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °³¼±Àº È޴뼺, ½ÅÁßÇÔ, »ç¿ë ÆíÀǼº¿¡ ´ëÇÑ È¯ÀÚµéÀÇ ÁÖ¿ä °ü½É»ç¸¦ ÇØ°áÇÏ¿© ȯÀÚÀÇ ÀÏ»ó »ýȰ¿¡ ÅëÇյǴ ³óÃà±â¸¦ ´õ¿í ¸Å·ÂÀûÀ¸·Î ¸¸µé°í ÀÖ½À´Ï´Ù.

¿ä¾ç ÇöÀåÀ̳ª Àα¸Åë°è¿¡ °ü°è¾øÀÌ ¼ö¿ä°¡ °¡Àå ¸¹ÀÌ Áõ°¡Çϰí ÀÖ´Â °÷Àº ¾îµðÀΰ¡?

ÀçÅà »ê¼Ò¹ß»ý±â¿¡ ´ëÇÑ ¼ö¿ä´Â ¸¸¼º ¹× ±Þ¼º±â ÀÌÈÄ È¸º¹±â ºÎ¹® ¸ðµÎ¿¡¼­ Áõ°¡Çϰí ÀÖÀ¸¸ç, COPD´Â ¿©ÀüÈ÷ ÁÖ¿ä ÀûÀÀÁõÀ¸·Î ºÏ¹Ì, À¯·´ ¹× ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ëÀÎµé »çÀÌ¿¡¼­ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ Àú»ê¼ÒÇ÷ÁõÀÌ ³²¾ÆÀִ ȯÀÚµéÀÇ Àå±âÀûÀÎ COVID °ü¸®·Î ÀÎÇØ º¸Á¶ »ê¼Ò¸¦ ÇÊ¿ä·Î ÇÏ´Â »õ·Î¿î °èÃþÀÌ µîÀåÇϰí ÀÖ½À´Ï´Ù. ½ÅÈï±¹¿¡¼­´Â ÀÇ·á ¼­ºñ½ºÀÇ º¸±Þ°ú º¸Çè Àû¿ë È®´ë¿¡ µû¶ó Àú¼Òµæ ¹× Áß»êÃþ °¡±¸ÀÇ ÀçÅà »ê¼Ò ¿ä¹ý¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

ÈÞ´ë¿ë »ê¼ÒÆ÷È­µµÃøÁ¤±â(POC)´Â ƯÈ÷ Ȱµ¿ÀûÀÎ ³ë³âÃþ¿¡¼­ ¼ÒÇüÀÇ Æí¸®ÇÑ À̵¿¼ºÀ» ¼±È£ÇÏ´Â µµ½Ã Áö¿ª¿¡¼­ ºü¸£°Ô º¸±ÞµÇ°í ÀÖ½À´Ï´Ù. À̿ʹ ´ëÁ¶ÀûÀ¸·Î, °íÁ¤Çü »ê¼Ò¹ß»ý±â´Â ¿©ÀüÈ÷ ħ»óÀ̳ª °Åµ¿ÀÌ ºÒÆíÇÑ È¯ÀÚµéÀ» À§ÇÑ ¼ö¿ä°¡ ÀÖ½À´Ï´Ù. ÀçÅÃÀÇ·á ±â°ü, ¿ÏÈ­ Ä¡·á Á¦°øÀÚ, ¿ø°ÝÀÇ·á Ç÷§ÆûÀº Á¾ÇÕÀûÀÎ Ä¡·á ÆÐŰÁö¿¡ ³óÃà ÀåÄ¡¸¦ ÅëÇÕÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á °ü±¤ ¹× Åð¿ø ÈÄ ÀçÅà ÀçȰ ÇÁ·Î±×·¥ÀÇ Áõ°¡´Â º´¿ø ¹Û¿¡¼­ Ä¡·á¸¦ Áö¼ÓÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÏ´Â ÀÛ°í Á¶ÀÛÇϱ⠽¬¿î ³óÃà ÀåÄ¡¿¡ ´ëÇÑ ¼ö¿ä¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ÀçÅà »ê¼Ò¹ß»ý±â ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù...

Àü ¼¼°èÀûÀ¸·Î ¸¸¼º È£Èí±âÁúȯÀÇ À¯º´·ü Áõ°¡¿Í °í·ÉÈ­ »çȸ¿¡¼­ÀÇ Àå±â Ä¡·áÀÇ Çʿ伺ÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ³óÃà±âÀÇ ¼ÒÇüÈ­, È¿À²È­, Áö´ÉÈ­¸¦ À§ÇÑ ±â¼ú ¹ßÀüÀº °¡Á¤ ȯ°æ¿¡¼­ÀÇ Ã¤Åà Ȯ´ë¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ºñ¿ë Àý°¨, ȯÀÚ ÆíÀǼº, Á¤¿ø °ü¸® µîÀÇ ÀÌÀ¯·Î º´¿ø Á᫐ ÀÇ·á¿¡¼­ ÀçÅÃÀÇ·á·ÎÀÇ ÀüȯÀº ºñ¿ë Àý°¨, ȯÀÚ ÆíÀǼº, Á¤¿ø °ü¸® µîÀ» À§ÇÑ ¿øµ¿·ÂÀÌ µÇ°í ÀÖÀ¸¸ç, COVID-19¿Í °°Àº °øÁߺ¸°Ç ºñ»ó»çŵµ »ê¼Ò ¿ä¹ý¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̰í ÀçÅà ȣÈí±â Ä¡·á ÀÎÇÁ¶ó ±¸ÃàÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

ƯÈ÷ ¼±Áø±¹ÀÇ ÀÇ·á ½Ã½ºÅÛ¿¡¼­ »óȯ Á¤Ã¥ ¹× ȯÀÚ Áö¿ø ÇÁ·Î±×·¥À» ÅëÇÑ Á¤ºÎ Áö¿øÀÇ Áõ°¡·Î ÀÎÇØ »ê¼Ò¹ß»ý±â´Â ´õ¿í °æÁ¦ÀûÀ¸·Î Á¢±ÙÇϱ⠽¬¿öÁö°í ÀÖ½À´Ï´Ù. ÇÑÆí, ¿þ¾î·¯ºí µðÀÚÀÎ, ¹èÅ͸® °­È­, ½Ç½Ã°£ ¿¬°á°ú °°Àº Á¦Ç° Çõ½ÅÀº À̵¿¿¡ ¹Î°¨ÇÑ È¯ÀÚ¿Í °£º´Àο¡°Ô ´õ¿í ¸Å·ÂÀûÀ¸·Î ´Ù°¡¿À°í ÀÖ½À´Ï´Ù. ÀçÅÃÀÇ·á±â±â À¯Åë ä³Î¿¡ ´ëÇÑ ÅõÀÚ È®´ë¿Í ¿ø°ÝÀÇ·áÀÇ È®»êÀº ½ÃÀå ħÅõ¸¦ °¡¼ÓÈ­ÇÏ°í ±â±âÀÇ Áö¼ÓÀûÀÎ ¾÷±×·¹À̵带 ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °³ÀÎÈ­µÈ ºñħ½ÀÀû, ºñħ½ÀÀû, ÀÚ°¡ °ü¸®Çü È£Èí±â Äɾ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó, ÀçÅà »ê¼Ò¹ß»ý±â´Â Àü ¼¼°èÀûÀ¸·Î ¸¸¼ºÁúȯ °ü¸®ÀÇ ÇÙ½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(ÈÞ´ëÇü ÀçÅà »ê¼Ò¹ß»ý±â, °íÁ¤Çü ÀçÅà »ê¼Ò¹ß»ý±â), ¸¶ÄÉÆÃ Ã¤³Î(Á÷Á¢ ¸¶ÄÉÆÃ, À¯Åë ¸¶ÄÉÆÃ, ·»Å» ¸¶ÄÉÆÃ, ±âŸ ¸¶ÄÉÆÃ Ã¤³Î), ÃÖÁ¾»ç¿ëÀÚ(ȨÄɾî ÃÖÁ¾»ç¿ëÀÚ, ºñȨÄɾî ÃÖÁ¾»ç¿ëÀÚ, COPD ȯÀÚ¿ë ¿¬±¸ ¼¾ÅÍ ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(ÃÑ 43°³»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¸ÅÃâ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù : Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù : ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м®:

¹Ì±¹ <> Áß±¹ <> ¸ß½ÃÄÚ <> ij³ª´Ù <> EU <> ÀϺ» <> Àεµ <> ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ® : Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Homecare Oxygen Concentrators Market to Reach US$1.8 Billion by 2030

The global market for Homecare Oxygen Concentrators estimated at US$1.3 Billion in the year 2024, is expected to reach US$1.8 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Portable Homecare Oxygen Concentrators, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Stationary Homecare Oxygen Concentrators segment is estimated at 3.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$356.2 Million While China is Forecast to Grow at 9.6% CAGR

The Homecare Oxygen Concentrators market in the U.S. is estimated at US$356.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$380.0 Million by the year 2030 trailing a CAGR of 9.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global Homecare Oxygen Concentrators Market - Key Trends & Drivers Summarized

Why Are Homecare Oxygen Concentrators Becoming Essential in Chronic Respiratory Care?

Homecare oxygen concentrators have become critical medical devices for patients managing chronic respiratory disorders such as COPD, pulmonary fibrosis, and long-term effects of COVID-19. These devices enable oxygen therapy at home by extracting and concentrating oxygen from ambient air, offering a safer and more convenient alternative to compressed gas cylinders. As the global population ages and respiratory diseases increase, the demand for reliable, compact, and user-friendly oxygen concentrators is growing rapidly.

The post-pandemic emphasis on home-based healthcare has further cemented the importance of these devices in respiratory management, especially for patients who require continuous or long-term oxygen support. The ability to reduce hospital admissions and improve quality of life makes concentrators attractive to both patients and healthcare providers. Government subsidies, insurance reimbursements, and public health programs are helping increase access in both developed and emerging markets. Their portability, cost-efficiency, and low-maintenance operation are making them indispensable in long-term homecare regimens.

How Are Design and Technological Advancements Improving Patient Outcomes?

Recent innovations are transforming the functionality and user experience of homecare oxygen concentrators. Modern units are designed to be lightweight, noise-reduced, and energy efficient, with compact footprints suitable for both fixed and portable use. Dual-mode units-capable of operating on AC and battery power-enable patients to stay mobile while receiving uninterrupted therapy. Pulse dose delivery, auto-adjusting flow rates, and altitude compensation features are being added to enhance adaptability across different activity levels and environments.

Digital connectivity is another emerging trend. Smart concentrators now offer Bluetooth or app integration, allowing patients and caregivers to monitor usage, oxygen purity, and maintenance alerts in real time. These features enable better compliance and early identification of faults. Advances in molecular sieve technology, compressor miniaturization, and heat management systems are allowing for longer operational life and quieter performance. Such improvements are addressing key patient concerns around portability, discretion, and usability-making concentrators more appealing for daily integration into patients’ lives.

Where Is Demand Growing Fastest Across Care Settings and Demographics?

The demand for homecare oxygen concentrators is growing across both chronic care and post-acute recovery segments. COPD remains the leading indication, with rising prevalence among elderly populations in North America, Europe, and increasingly in Asia Pacific. Long COVID management, especially in patients with residual hypoxemia, has introduced a new demographic requiring supplemental oxygen. In emerging economies, greater healthcare outreach and insurance coverage are expanding access to home oxygen therapy among low- and middle-income households.

Portable oxygen concentrators (POCs) are witnessing rapid uptake in urban centers, particularly among active elderly populations who prefer compact, travel-friendly options. In contrast, stationary models remain in demand for bedridden or mobility-limited patients. Home healthcare agencies, palliative care providers, and telemedicine platforms are integrating concentrators into holistic care packages. Additionally, the rise of medical tourism and home-based post-discharge rehabilitation programs is contributing to demand for compact, easy-to-operate concentrators that support continuity of care outside hospital settings.

The Growth in the Homecare Oxygen Concentrators Market Is Driven by Several Factors…

It is driven by the rising global incidence of chronic respiratory diseases and the long-term care requirements of aging populations. Technological advancements that make concentrators more compact, efficient, and intelligent are supporting greater adoption in home environments. The shift in healthcare delivery from hospital-centric to home-based care-driven by cost savings, patient comfort, and capacity management-is another major catalyst. Public health emergencies such as COVID-19 have also raised awareness of oxygen therapy and accelerated infrastructure for at-home respiratory care.

Increasing government support through reimbursement policies and patient assistance programs is making concentrators more financially accessible, particularly in developed healthcare systems. Meanwhile, product innovation-such as wearable designs, battery enhancements, and real-time connectivity-is expanding appeal across mobility-conscious patients and caregivers. Growing investment in home medical device distribution channels, coupled with rising telehealth adoption, is helping drive faster market penetration and ongoing device upgrades. As demand for personalized, non-invasive, and self-managed respiratory care grows, homecare oxygen concentrators are becoming a cornerstone of chronic disease management globally.

SCOPE OF STUDY:

The report analyzes the Homecare Oxygen Concentrators market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Portable Homecare Oxygen Concentrators, Stationary Homecare Oxygen Concentrators); Marketing Channel (Direct Marketing, Distribution Marketing, Rental Marketing, Other Marketing Channels); End-Use (Home Care End-Use, Non-Homecare End-Use, Research Centers for COPD Patients End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â